3 Top Dividend Stocks to Buy in December


  • AbbVie is a Dividend King that has proven its resilience.

  • Ares Capital offers an ultra-high yield, with solid near-term and long-term growth prospects.

  • Enbridge provides a highly reliable dividend plus attractive growth potential.

  • 10 stocks we like better than Ares Capital ›

Did you know that the latter part of December is historically a great time to invest in the stock market? There’s even a phenomenon known as the Santa Claus rally, where stocks often rise beginning in the last few days of the year.

But investing in stocks that pay juicy dividends can pay off even if Santa doesn’t deliver year-end merriment. Here are three top dividend stocks to buy in December.

A white board with "Dividends" in the center surrounded by images.
Image source: Getty Images.

AbbVie‘s (NYSE: ABBV) dividend yield of slightly above 3% isn’t as high as it has been in the past. However, this isn’t because of dividend cuts. The major drugmaker has increased its dividend for 53 consecutive years, making it a member of the Dividend Kings – an elite group of stocks that have raised their dividends for at least 50 years in a row.

The reason for AbbVie’s lower yield is more positive: Its stock has soared this year. Has this strong performance made AbbVie’s valuation overly frothy? Not at all. Its shares still trade at a forward price-to-earnings ratio of only 16.8, which is lower than the S&P 500 (SNPINDEX: ^GSPC) healthcare sector’s average forward earnings multiple of 18.7.

Two autoimmune disease drugs, Rinvoq and Skyrizi, stand out as AbbVie’s primary growth drivers. Combined sales of these two products increased by more than 40% year over year in the latest quarter.

The success of Rinvoq and Skyrizi also highlights AbbVie’s resilience. In 2023, the company faced the loss of exclusivity in the U.S. for its longtime best-selling drug, Humira. However, AbbVie prepared well for this patent cliff by investing in internal research and development, as well as making strategic acquisitions. Those investments are paying off nicely now.

Ares Capital (NASDAQ: ARCC) hasn’t been such a big winner so far in 2025. However, the long-term picture for the business development company (BDC) looks much better than the short term. Ares Capital has delivered total returns that are more than 40% higher than those of the S&P 500 since its IPO in 2004.

Those total returns continue to be boosted by Ares Capital’s dividend. The BDC’s forward dividend yield tops 9.1%. Ares Capital has either maintained or grown its dividend for more than 16 consecutive years.

The company’s long-term prospects look bright. Demand for direct lending is growing. Ares Capital estimates its total addressable market to be around $5.4 trillion, encompassing both the traditional middle market and organizations with annual revenue exceeding $1 billion.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Pkv Games DominoQQ Qiu Qiu
Mix Parlay